Celltrion Publishes Post-Hoc Phase 3 Clinical Analysis of 'Zympendra' in International Journal

Celltrion announced on April 2 that a paper detailing the results of a post-hoc analysis from the global Phase 3 clinical trial of 'Zympendra' (the ...
Medscape

Tirzepatide Effective Despite Weight-Inducing Meds

Tirzepatide is linked to significant weight loss in adults with overweight or obesity who are taking weight-inducing medications, suggesting benefits even when these therapies are continued.
Business Wire

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...
Medscape

Arterial Stiffness Changes Linked to Development of Dementia in SPRINT Post Hoc Analysis

Pulse wave velocity, calculated from age and blood pressure changes, was associated with significant dementia risk in a post ...
The American Journal of Managed Care

Post Hoc Analysis Findings Offer Guidance for Anemia Management in Myelofibrosis: Pankit Vachhani, MD

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
Nasdaq

CalciMedica Presents New Data From Post Hoc Analysis Of Phase 2 CARDEA Study Of Auxora

(RTTNews) - CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, Tuesday said it presented new data based on a post-hoc analysis from the previously completed Phase 2 CARDEA study of ...
Nasdaq

Amicus Therapeutics Publishes Positive Post-Hoc Analysis of Cipaglucosidase Alfa-Atga + Miglustat in Late-Onset Pompe Disease

Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
EurekAlert!

New post-hoc analysis shows patients whose clinicians had access to GeneSight results for depression treatment are more likely to feel better sooner

SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.